Treatment profile and complications associated with cryotherapy for localized prostate cancer: A population-based study

Calpurnia B. Roberts, PhD\textsuperscript{a}, Thomas L. Jang, MD, MPH\textsuperscript{b,c,d}, Yu-Hsuan Shao, PhD\textsuperscript{b}, Shaum Kabadi, MPH\textsuperscript{e}, Dirk F. Moore, PhD\textsuperscript{f}, and Grace L. Lu-Yao, PhD\textsuperscript{b,d,g,h}

\textsuperscript{a}State University of New York Downstate Medical Center, Brooklyn, NY
\textsuperscript{b}Cancer Institute of New Jersey, New Brunswick, NJ
\textsuperscript{c}Department of Surgery, Division of Urology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ
\textsuperscript{d}The Dean and Betty Gallo Prostate Cancer Center
\textsuperscript{e}Department of Epidemiology and Biostatistics, The School of Public Health, Drexel University, Philadelphia, PA
\textsuperscript{f}Department of Biostatistics, The School of Public Health, University of Medicine and Dentistry in New Jersey, Piscataway, NJ
\textsuperscript{g}Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ
\textsuperscript{h}Department of Epidemiology, The School of Public Health, University of Medicine and Dentistry in New Jersey, Piscataway, NJ

Abstract

The aim of this study was to assess the treatment patterns and 3 to 12-month complication rates associated with receiving prostate cryotherapy in a population-based study. Men > 65 years diagnosed with incident localized prostate cancer in Surveillance Epidemiology End Results (SEER) - Medicare linked database from 2004 to 2005 were identified. A total of 21,344 men were included in the study, of which 380 were treated initially with cryotherapy. Recipients of cryotherapy versus aggressive forms of prostate therapy (i.e. radical prostatectomy or radiation therapy) were more likely to be older, have one co-morbidity, low income, live in the South, and be diagnosed with indolent cancer. Complication rates increased from 3 to 12 months following...
cryotherapy. By the twelfth month, the rates for urinary incontinence, lower urinary tract obstruction, erectile dysfunction, and bowel bleeding reached 9.8%, 28.7%, 20.1%, and 3.3%, respectively. Diagnoses of hydronephrosis, urinary fistula, or bowel fistula were not evident. The rates of corrective invasive procedures for lower urinary tract obstruction and erectile dysfunction were both <2.9% by the twelfth month. Overall, complications post cryotherapy were modest; however, diagnoses for lower urinary tract obstruction and erectile dysfunction were common.

Keywords
cryotherapy; Medicare; prostatic neoplasms; Surveillance, Epidemiology and End Results program

Introduction
Since the introduction of prostate specific-antigen (PSA) screening, an increasing number of men are being diagnosed with low grade, low stage, small volume cancers that are potentially biologically indolent. Consequently, choosing whether and how to treat these tumors remains challenging. Men newly diagnosed with low-risk prostate cancer are frequently treated with standard therapies (i.e. radical prostatectomy, external beam radiation therapy (EBRT), brachytherapy, androgen deprivation therapy (ADT), or conservative management), [1], which are associated with high overall, cancer-specific, and biochemical-recurrence free survival. However, radical prostatectomy, radiation therapy, and ADT are accompanied by side effects (e.g. bladder and bowel dysfunction) that may impact negatively on health related quality of life. Conversely, conservative management may induce anxiety and elevate stress levels [2]. As such, renewed interest has emerged in utilizing minimally invasive approaches, such as cryotherapy, to treat men diagnosed with clinically, localized prostate cancer.

Cryotherapy has become more widespread in practice due to a better understanding of cryobiology [3], introduction of third-generation cryoprobes, and improvements in biopsy and imaging techniques, which have enhanced the ability to map the foci and location of tumors within the prostate and subsequently reduce morbidity while improving effectiveness [3–5].

Although cryotherapy has been identified as a potential treatment option for men with clinically organ-confined disease by the American Urological Association, [3] there is no formal definition of cryotherapy eligible tumors and a lack of information regarding the actual recipients of cryotherapy. Moreover, morbidity associated with cryotherapy has been primarily reported from single hospital-based studies, typically in highly selected patients [6–14]. Thus, in a population-based study, we identify the risk profile of men with clinically localized prostate cancer initially treated with cryotherapy and characterize post treatment-related complications.
Material and Methods

Data for this study was obtained from the 16 tumor registries participating in the National Cancer Institute’s Surveillance Epidemiology Ends Results (SEER) program database linked to Medicare administrative claims. The SEER program monitors approximately 26% of the United States population and has complete ascertainment in 98% of cases [15]. Our study cohort consisted of men ≥66 years diagnosed with incident, localized prostate cancer (ICD-O-3 site code C619) while enrolled in Medicare between 2004 and 2005. All patients were initially treated with cryotherapy, a form of aggressive standard therapy (i.e. radical prostatectomy or radiation therapy) or non-aggressive standard therapy (ADT or conservative management) within one year of being diagnosed with prostate cancer. Men with advanced prostate cancer (T3 or T4) (n = 2,519) or prior cancers (n = 4,896) were excluded. Additional exclusion criteria included patients whose diagnosis of prostate cancer was obtained from autopsy or death certificate (n=745) or tumor pathology not consistent with adenocarcinoma (n =2,167). Given that transurethral resection of the prostate (TURP) increases the risk of urinary complications, men with a history of TURP (n =32) or those who underwent TURP in combination with cryotherapy (n = 191) were excluded [16]. Men with unknown Gleason score (n=1,120), PSA level (n =4,589), clinical stage (n=1,249), or covariates (n = 52) were also excluded. The final study cohort consisted of 21,344 men newly diagnosed with localized prostate cancer.

Treatment

Cryotherapy and standard therapies were administered within one year following initial diagnosis of prostate cancer. Cryotherapy was identified from Medicare inpatient and outpatient claims using International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) procedure code 60.62, Current Procedural Terminology (CPT) code 55873, Health Care Financing Administration Common Procedure Coding System (HCPCS) codes G0160 and G0161, and SEER data. Standard forms of therapy were identified from Medicare billing codes and SEER data.

Complications

ICD-9/CPT/HCPCS codes and Medicare claims data were utilized to ascertain the prevalence of diagnoses and invasive procedures reported for urinary, bowel, and sexual function related complications occurring three, six, and twelve-months after cryotherapy. Patients with a Medicare claim of urinary, rectal, or erectile dysfunction diagnoses or procedural related complications prior to cryotherapy were excluded in order to identify the prevalence of post-treatment complications, which included lower urinary tract obstruction, erectile dysfunction, urinary incontinence, bowel bleeding, hydronephrosis, urinary fistula, and bowel fistula. The medical codes for diagnoses and procedures for the aforementioned complications are provided in Appendix A.

Covariates

Demographic variables included age, race, marital status, income, geographic region, PSA, Gleason score, clinical stage, cancer recurrence risk level, and Charlson co-morbidity. Charlson co-morbidity score was derived from Medicare claims during the year prior to
prostate cancer diagnosis by using a validated algorithm [17]. Risk level, a measure of
disease progression and PSA failure, was defined based on the risk model defined by the
National Comprehensive Cancer Network [17]. Low risk included clinical stage ≤ T2a, PSA
level ≤ 10 ng/ml, Gleason score ≤ 6; intermediate risk included clinical stage T2b–T2c, PSA
> 10 and ≤ 20 ng/ml, Gleason score = 7; and high risk included PSA > 20 ng/ml, Gleason
score ≥ 8 [18].

**Statistical analysis**

Multivariate logistic regression was utilized to estimate odds ratios (OR) and 95%
confidence intervals (CI) for the association between patient and tumor characteristics and
the selection of cryotherapy as opposed to aggressive or nonaggressive standard forms of
therapy. Rates of urinary, bowel, and sexual function related diagnoses and corrective
invasive procedures occurring three, six, and twelve months following cryotherapy are
presented. All analyses were performed using SAS statistical software (version 9.1, SAS
Institute, Cary, NC). The study was approved by the University of Medicine and Dentistry
of New Jersey Institutional Review Board.

**Results**

A total of 380 patients (1.8%) underwent cryotherapy as initial treatment for localized
prostate cancer and had at least one year of follow-up after cryotherapy. The majority of
participants treated with cryotherapy, radical prostatectomy, or radiation therapy were 66–74
years, 61.3%, 92.2%, and 62.6%, respectively, whereas the majority of men given ADT or
conservative management were ≥75 years, 68.8% and 54.4%, respectively. Most men
treated with cryotherapy were diagnosed as having intermediate-risk disease (50%),
followed by low-risk (33.7%) and high-risk (16.1%) disease. Of cryotherapy patients, 70.5%
had no co-morbidities, 22.1% had one co-morbidity, and 7.4% had at least two co-
morbidities.

In multivariate analyses, age, marital status, income, geographic region, Gleason score, and
Charlson co-morbidity score were significantly related to the selection of cryotherapy over
aggressive therapies as initial treatment (Table 2). For instance, men ≥75 years were 1.58
(95% CI: 1.27, 1.95) times as likely to have cryotherapy than men 66–74 years. Income was
inversely associated with the use of cryotherapy, such that men from low income were 1.46
(95% CI: 1.10, 1.93) times as likely to receive cryotherapy than men from higher income.
Gleason score was the only tumor-related characteristic that was associated with cryotherapy
use.

High-risk patients were less likely to be treated with cryotherapy than low-risk patients (OR
= 0.70; 95% CI: 0.51, 0.96) (Table 3). The use of cryotherapy did not vary between men
with intermediate or low-risk disease (OR = 1.00; 95% CI: 0.80, 1.26).

Within three months after undergoing cryotherapy, 23.7% of men were diagnosed with or
treated for lower urinary tract obstruction (Table 4). Erectile dysfunction, urinary
incontinence, and bowel bleeding were prevalent in 4.0%, 3.8%, and <2.9% of men,
respectively. By six months, the rate of erectile dysfunction more than tripled and urinary
incontinence doubled. Twelve months following cryotherapy, lower urinary tract obstruction, erectile dysfunction, urinary incontinence, and bowel bleeding rose to 28.7%, 20.1%, 9.8%, and 3.3% respectively. No man had a diagnosis or corrective invasive procedure within twelve months following cryotherapy for hydronephrosis, urinary fistula, or bowel fistula.

Of the patients diagnosed with urinary incontinence, no one had a corrective invasive procedure, <11 of men had a procedure to alleviate lower urinary tract obstruction or to ameliorate erectile dysfunction.

Discussion

In this population-based study, we found that cryotherapy remains a novel strategy to treat men initially diagnosed with clinically localized prostate cancer. We observed that besides disease-risk level that several demographic characteristics are significantly associated with receiving cryotherapy. In addition, among men with no prior history of treatment-related complications, the rates of urinary incontinence, hydronephrosis, bowel bleeding, urinary fistula, and bowel fistula post treatment were minimal. However, the rates of lower urinary tract obstruction and erectile dysfunction are common, but there is little need for ancillary corrective, invasive procedures.

Although, men with high-risk disease were significantly less likely to receive cryotherapy than men with low-risk disease, nearly one in five men administered cryotherapy had high-risk disease (16.1%), indicating that in clinical practice cryotherapy is being used in patients with more aggressive cancers, (i.e. men with PSA levels >20ng/ml or Gleason score 8–10). Albeit selection criteria for men undergoing prostate cryotherapy have yet to be definitively established, optimal candidates for this procedure generally include those with lower stage, lower volume disease with PSA levels <20 ng/ml [19].

Interestingly, an inverse association between income and cryotherapy was observed. This may indicate that cryotherapy is becoming an attractive alternative for men with lesser means possibly in part because it is associated with shorter hospital stay, faster recovery time, and is theoretically less costly than standard therapy [20]. Our findings support past studies, which have demonstrated that men with lower socioeconomic status were less likely to receive aggressive therapy in comparison to their richer counterparts [21]. For example, Cooperberg et al. recently reported that a greater percentage of men with an annual income of <$20,000, $20,000–$30,000, or $30,00–$50,000 were treated with cryotherapy than men with an annual income ≥$50,000 [22].

Of particular significance in our study, is the finding that the proportion of patients developing erectile dysfunction or urinary incontinence may increase over time, suggesting that the effects of cryotherapy may not only arise immediately after cryotherapy, but remotely as well. For instance, from six months to twelve months following treatment, the rates of erectile dysfunction increased from 13.2% to 20.1% and urinary incontinence rose from 7.9% to 9.8%.
Complications occurring after cryotherapy have been widely studied in small single hospital-based studies. Reports of urinary incontinence ranged from 1.3 to 9.5% [7,9–12,14, 23,24, 25], urinary strictures from 1.7% to 3.4% [10,12,14], lower urinary tract obstruction/retention from 13% to 23% [24, 26–28], bowel bleeding was 2.0% [12], and erectile dysfunction from 47% to 94.9% [7,10,11,14]. Consistently, cryotherapy was found to be associated with a low rate of fistulas (<1%) several years after the procedure [7,10–14]. In our cohort of men receiving prostate cryotherapy, no urinary or bowel fistulas or hydronephrosis were reported and bowel bleeding was observed to be low twelve months after cryotherapy. The twelve-month rates of lower urinary tract obstruction and urinary incontinence in this study were greater than reported in prior studies. The higher complication rates found in this study may reflect differences in the definition of the complications or the use of population-based data as opposed to hospital-based data. The twelve-month rates of lower urinary tract obstruction and urinary incontinence in this study were greater than reported in prior studies. The higher complication rates found in this study may reflect differences in the definition of the complications, the use of population-based data as opposed to hospital-based data, or publication bias. In particular, the higher rates of postoperative urinary incontinence may be indicative of the higher rates of mild to severe urinary symptoms in older men [29, 30] that often is underreported [30, 31], and a larger prostate volume [32] which interferes with urinary incontinence. Thus, the older men in this study may have some degree of pre-existing urinary dysfunction or larger prostate, which may augment their risk of urinary incontinence post cryotherapy. The rate of erectile dysfunction in this study was lower than previous estimates and may be attributed to our study population consisting of men 66 years of age or older. Older men may not be as concerned about reporting and treating erectile dysfunction as younger men. In addition, some cases of erectile dysfunction may not have been identified because we lacked validated instruments to assess erectile dysfunction such as the International Index of Erectile Function [33], the Quality of Erection Questionnaire [34], or the Sexual Health Inventory for Men [35]. It is also feasible that the rate of erectile dysfunction may have been underestimated during the study period because some patients may have used devices or agents (e.g. vacuum erection device, internal penile pump, phosphodiesterase type 5 inhibitors) to rectify their erectile dysfunction.

The postoperative complication rates may also vary across studies because of differences in tumor characteristics (e.g. gland size), rates of complications pre-cryotherapy (e.g. impotency), duration of follow-up, definition of complications, inclusion of men with a history of TURP, use of previous treatments (e.g. external beam radiation therapy), and the generation of the cryotherapy device(s).

An advantage of the present study is that updated data pertaining to cryotherapy was utilized. Previous studies reported outcomes when cryotechnology and imaging were evolving [7,9–14,23]. Since then, further technological advancements in the field have been achieved, such as the use of argon gas instead liquid nitrogen, which has enabled cryotherapy to be delivered in a more precise, safer, and efficacious manner [3, 36]. Consequently, our findings provide valuable insight into the prevalence of morbidity associated with this treatment in a technologically more advanced era.
Certain limitations of our study warrant mention. Although our findings likely reflect clinical practice in the United States because the SEER database covers 26% of the United States population, we were unable to explore the influence of other pertinent risk factors, such as gland volume and configurations. Additionally, given that the data for this study were extracted from administrative claims data, we were unable to evaluate erectile dysfunction and urinary complications using validated instruments of quality of life [33–35]. Thus, the rates of these complications may be underestimated. Further, due to the inherent limitations of using administrative claims data we were unable to decipher the generation of the cryotherapy devices that were performed on patients. However, given that the procedures occurred within a narrow window of time from 2004 to 2005, variation in the generation of the cryotherapy devices utilized was most likely minimized.

The results from this study may not be generalizable to younger men because Medicare consists of men 65 years and older. We also could not distinguish between whole gland cryotherapy and focal cryotherapy, as current procedural codes do not exist to allow for this differentiation. Finally, the use of administrative claims to estimate treatment-related complications may result in an underestimation of the true complication prevalence.

In summary, our findings provide an estimate of contemporary post-treatment complications associated with cryotherapy. The results from this study suggest that among men diagnosed with localized prostate cancer that morbidity post cryotherapy is modest; lower urinary tract obstruction and erectile dysfunction remain common following cryotherapy; complications can manifest even one year after treatment; and a small proportion of men may require invasive corrective procedures to address these complications. Patients should be fully informed of the complications presented herein as well as the lack of well-controlled or randomized studies supporting its efficacy.

Acknowledgements

The authors acknowledge the efforts of the Applied Research Branch, Division of Cancer Prevention and Population Science, NCI; the Office of Information Services, and the Office of Strategic Planning, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The performance and design of this study was reviewed and approved by both the National Cancer Institute (NCI) and Center for Medicare and Medicaid Services (CMS). This study was supported by an award from the Robert Wood Johnson Foundation grant # 60624 and by the biometric Shared Resource(s) of The Cancer Institute of New Jersey (P30CA072720).

References

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22:2141–2149. [PubMed: 15169800]
2. Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005; 104:467–478. [PubMed: 15959911]
3. Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008; 180:1993–2004. [PubMed: 18817934]
4. Saliken JC, Donnelly BJ, Rewcastle JC, et al. The evolution and state of modern technology for prostate cryosurgery. Urology. 2002; 60:26–33. [PubMed: 12206845]
5. Sartor AO, Hricak H, Wheeler TM, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008; 72:S12–S24. [PubMed: 19095124]
6. Malcolm JB, Fabrizio MD, Barone BB, et al. Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer. J Urol. 2010; 183:1822–1828. [PubMed: 20303100]

7. Coogan CL, McKiel CF. Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. J Urol. 1995; 154:1813–1817. [PubMed: 7563354]

8. Ellis DS, Manny TB Jr, Newcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology. 2007; 70:9–15. [PubMed: 18194712]

9. Donnelly BJ, Saliken JC, Ernst DS, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology. 2002; 60:645–649. [PubMed: 12385926]

10. Aus G, Pileblad E, Hugosson J. Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. Eur Urol. 2002; 42:133–138. [PubMed: 12160583]

11. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002; 60:3–11. [PubMed: 12206842]

12. Cohen JK. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Urology. 1996; 48:178–180. [PubMed: 8753725]

13. Prepelica KL, Okeke Z, Murphy A, et al. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005; 103:1625–1630. [PubMed: 15747374]

14. Long JP, Fallick ML, LaRock DR, et al. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol. 1998; 159:477–484. [PubMed: 9649266]

15. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40:IV-3–IV-18.

16. Shinohara K, Connolly JA, Presti JC Jr, Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol. 1996; 156:115–121. [PubMed: 8648771]

17. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000 Dec.53:1258–1267. [PubMed: 11146273]

18. [Accessed [March 15, 2010]] National Comprehensive Cancer Network. 2010. Available at: http://www.nccn.org

19. Finley DS, Pouliot F, Miller DC, et al. Primary and salvage cryotherapy for prostate cancer. Urol Clinics of North America. 2010; 37:67–82.

20. Ritch CR, Katz AE. Prostate cryotherapy: current status. Curr Opin Urol. 2009; 19:177–181. [PubMed: 19195130]

21. Kane CJ, Lubeck DP, Knight SJ, et al. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003; 62:1035–1039. [PubMed: 14665350]

22. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28:1117–1123. [PubMed: 20124165]

23. Wong WS, Chinn DO, Chinn M, Chinn J, Tom WL. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer. 1997; 9:963–974. [PubMed: 9041159]

24. Long JP, Bahn D, Lee F, Shinohara K, Chinn Do, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001; 57:518–523. [PubMed: 11248631]

25. Kimura M, Mouraviev V, Tsivian M, Moreira DM, Mayes JM, Polascik TJ. Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoaablation. Urology. 2010; 76:1258–1265. [PubMed: 19963257]

26. Long JP. Is there a role for cryoablation of the prostate in the management of localized prostate carcinoma? Hematol Oncol Clin North Am. 1996; 10:675–690. [PubMed: 8773504]

27. Shinohara K, Rhee B, Presti JC Jr, Carroll PR. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol. 1997; 158:2206–2210. [PubMed: 9366345]

28. Wake RW, Hollabaugh RS Jr, Bond KH. Cryosurgical ablation of the prostate for localized adenocarcinoma: a preliminary experience. J Urol. 1996; 155:1663–1666. [PubMed: 8627849]
29. Markland AD, Goode PS, Redden DT. Prevalence of Urinary Incontinence in Men: Results from the National Health and Nutrition Examination Survey. J Urol. 2010; 84:1022–1027. [PubMed: 20643440]

30. Diokno AC, Estanol MVC, Ibrahim A, et al. Prevalence of urinary incontinence in community dwelling men: a cross sectional nationwide epidemiological survey. International Urology and Nephrology. 2007; 39:129–136. [PubMed: 17086446]

31. Dugan E, Roberts CP, Cohens SJ, et al. Why older community-dwelling adults do not discuss urinary incontinence with their primary care physicians. J AM Geriatr. 2001; 49:462–465.

32. Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53:581–589. [PubMed: 10096388]

33. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49:822–830. [PubMed: 9187685]

34. Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impotence Res. 2002; 14:242–250.

35. Wei J, Dunn R, Litwin M, Sandler H, Sanda M. “Development and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men with Prostate Cancer”. Urology. 2000; 56:899–905. [PubMed: 11113727]

36. De La Taille A, Benson MC, Bagiella E, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000; 85:281–286. [PubMed: 10671882]
Table 1

Characteristics of patients treated with cryotherapy and standard forms of therapy for incident localized prostate cancer, SEER-Medicare.

| Characteristics | Cryotherapy (n=380) | Aggressive standard therapies | Non-aggressive standard therapies |
|-----------------|--------------------|-------------------------------|-----------------------------------|
|                 | Radical Prostatectomy (n=3,960) | Radiation Therapy (n=10,757) | ADT (n=3,399) | Conservative Management (n=2,848) |
| Age (yrs)       |                   |                               |                                  |                                |
| 66–74           | 61.3              | 92.2                          | 37.5                             | 68.8                           | 45.6                           |
| 75+             | 38.7              | 7.8                           | 31.2                             | 66.8                           | 54.4                           |
| Race            |                   |                               |                                  |                                |                                |
| White           | 81.1              | 83.9                          | 82.2                             | 77.8                           | 78.3                           |
| Black           | 12.1              | 8.0                           | 10.4                             | 13.6                           | 14.7                           |
| Other           | 6.8               | 8.1                           | 7.4                              | 8.7                            | 7.0                            |
| Marital Status  |                   |                               |                                  |                                |                                |
| Married         | 66.8              | 81.8                          | 75.0                             | 56.4                           | 57.3                           |
| Unmarried       | 22.1              | 14.5                          | 19.6                             | 23.0                           | 24.0                           |
| Unspecified     | 11.1              | 3.7                           | 5.3                              | 20.7                           | 18.8                           |
| Income $        | $44,315           | $51,582                       | $49,526                          | $79,257                        | $46,088                        |
| Median (IQR)    | ($33,090, $57,677) | ($39,208, $70,418)           | ($36,371, $66,651)              | ($31,597, $59,650)             | ($33,294, $63,501)             |
| Region          |                   |                               |                                  |                                |                                |
| South           | 32.4              | 12.4                          | 17.4                             | 20.5                           | 18.1                           |
| North Central   | 7.9               | 12.6                          | 12.6                             | 11.8                           | 10.0                           |
| Northeast       | 10.0              | 10.4                          | 26.5                             | 17.8                           | 15.2                           |
| West            | 49.7              | 64.7                          | 43.5                             | 49.9                           | 56.7                           |
| PSA (ng/ml)     |                   |                               |                                  |                                |                                |
| 0–2.5           | 3.7               | 5.7                           | 5.4                              | 4.5                            | 6.3                            |
| 2.6– 4.0        | 6.4               | 8.4                           | 6.3                              | 3.6                            | 6.3                            |
| 4.1– 10.0       | 65.3              | 66.8                          | 60.8                             | 36.8                           | 57.0                           |
| 10.1–19.9       | 16.6              | 13.4                          | 18.2                             | 24.8                           | 17.5                           |
| ≥20             | 8.2               | 5.8                           | 9.3                              | 30.3                           | 13.0                           |
| Gleason Score   | 46.1              | 36.8                          | 48.5                             | 32.7                           | 64.3                           |
| Characteristics | Cryotherapy (n=380) | Aggressive standard therapies | Non-aggressive standard therapies |
|-----------------|---------------------|-------------------------------|----------------------------------|
|                 | Radical Prostatectomy (n= 3,960) | Radiation Therapy (n=10,757) | ADT (n=3,399) | Conservative Management (n=2,848) |
| 7               | 44.2                | 49.8                          | 36.7                            | 37.3 | 24.8 |
| 8–10            | 9.7                 | 13.4                          | 14.9                            | 30.0 | 10.9 |
| **Clinical Stage** |                     |                               |                                 |      |      |
| T1              | 50.5                | 55.3                          | 57.1                            | 44.2 | 52.7 |
| T2              | 49.5                | 44.7                          | 42.9                            | 55.8 | 47.3 |
| **Risk**        |                     |                               |                                 |      |      |
| Low             | 33.7                | 28.1                          | 34.6                            | 17.7 | 46.6 |
| Intermediate    | 50.3                | 54.0                          | 44.2                            | 36.0 | 34.4 |
| High            | 16.1                | 18.0                          | 21.3                            | 46.3 | 19.0 |
| **Charlson Co-morbidity Score** |             |                               |                                 |      |      |
| 0               | 70.5                | 84.0                          | 73.8                            | 66.1 | 72.6 |
| 1               | 22.1                | 12.8                          | 18.1                            | 20.6 | 17.7 |
| 2+              | 7.4                 | 3.2                           | 8.1                             | 13.3 | 9.8  |

IQR = Interquartile Range; ADT = Androgen Deprivation Therapy

Chi-square test used to assess the independence of patient demographic and clinical characteristics across treatment groups. All p-values were <0.001.

1 Radiation therapy includes external beam radiation therapy and brachytherapy

2 Unmarried consists of men reported being separated, divorced, or widowed

3 Patients were categorized into three risk groups on the basis of clinical classification, PSA level and Gleason score: low-risk (T1–T2a and PSA level <10 ng/mL and Gleason score 2–6), intermediate-risk (T2b–T2c or 10 ≤ PSA ≤ 20 ng/mL or Gleason score = 7) and high-risk (PSA level >20ng/mL or Gleason score 8–10).
Table 2

Adjusted\(^1\) Odds Ratios (95% Confidence Intervals) for factors associated with the selection of cryotherapy instead of aggressive standard therapy\(^2\) in men diagnosed with incident localized prostate cancer, SEER-Medicare.

| Characteristics          | OR     | 95% CI     | p-value |
|--------------------------|--------|------------|---------|
| **Age (yrs)**            |        |            |         |
| 75+                      | 1.58   | (1.27, 1.95)| <0.001 |
| 66–74                    | Referent|            |         |
| **Race**                 |        |            |         |
| Black/Other              | 0.99   | (0.75, 1.29)| 0.910  |
| White                    | Referent|            |         |
| **Marital Status**\(^3\) |        |            |         |
| Unmarried/Unspecified    | 1.66   | (1.33, 2.07)| <0.001 |
| Married                  | Referent|            |         |
| **Income**               |        |            |         |
| Lowest Tertile           | 1.46   | (1.10, 1.93)| 0.008  |
| Middle Tertile           | 1.35   | (1.03, 1.77)| 0.031  |
| Highest Tertile          | Referent|            |         |
| **Region**               |        |            |         |
| South                    | 1.81   | (1.42, 2.31)| <0.001 |
| North Central            | 0.55   | (0.37, 0.81)| 0.003  |
| Northeast                | 0.45   | (0.31, 0.64)| <0.001 |
| West                     | Referent|            |         |
| **PSA (ng/ml)**          |        |            |         |
| 0.1–≤10                  | Referent|            |         |
| 10.1–19.9                | 0.92   | (0.69, 1.21)| 0.544  |
| ≥20                      | 0.95   | (0.65, 1.40)| 0.805  |
| **Gleason Score**        |        |            |         |
| 2–6                      | Referent|            |         |
| 7                        | 1.04   | (0.84, 1.29)| 0.732  |
| 8–10                     | 0.60   | (0.41, 0.86)| 0.006  |
| **Clinical stage**       |        |            |         |
| T2                       | 1.22   | (0.99, 1.50)| 0.059  |
| T1                       | Referent|            |         |
| **Charlson Co-Morbidity Score** | | | |
| 0                        | Referent|            |         |
| 1                        | 1.41   | (1.10, 1.81)| 0.008  |
| 2+                       | 1.15   | (0.77, 1.71)| 0.498  |

\(^1\) Adjusted for patient and tumor characteristics included in the Table.
\(^2\) Aggressive standard therapies include radical prostatectomy, external beam radiation therapy, and brachytherapy.
\(^3\) Unmarried consists of men reported being separated, divorced, or widowed.
Table 3

The adjusted\(^1\) association between the selection of cryotherapy instead of aggressive\(^2\) standard therapies in men diagnosed with incident localized prostate cancer, SEER-Medicare.

| NCCN Criterion\(^3\) | OR    | 95% CI     | p-value |
|----------------------|-------|------------|---------|
| High                 | 0.70  | (0.51, 0.96) | 0.026   |
| Intermediate         | 1.00  | (0.80, 1.26) | 0.986   |
| Low                  | Referent |           |         |

\(^1\) Adjusted for age, race, marital status, income, region, and Charlson Co-morbidity Score.

\(^2\) Aggressive standard therapies include radical prostatectomy, external beam radiation therapy, and brachytherapy.

\(^3\) Patients were categorized into three risk groups on the basis of clinical classification, PSA level and Gleason score: low-risk (T1–T2a and PSA level <10 ng/mL and Gleason score 2–6), intermediate-risk (T2b–T2c or 10 ≤ PSA ≤ 20 ng/mL or Gleason score = 7) and high-risk (PSA level >20 ng/mL or Gleason score 8–10).
Table 4

Combined diagnoses and procedural related complications reported 3, 6, and 12 months after cryotherapy in men diagnosed with incident localized prostate cancer and no prior history of treatment related morbidity, SEER-Medicare.

| Complication                          | 3 months | 6 months | 12 months |
|---------------------------------------|----------|----------|-----------|
|                                       | n        | %        | n        | %        |
| 1 Lower Urinary Tract Obstruction     | 78       | 23.7     | 90       | 27.4     | 94       | 28.7     |
| 2 Erectile Dysfunction                | 14       | 4.2      | 46       | 13.2     | 70       | 20.1     |
| 3 Urinary Incontinence                | 14       | 3.8      | 29       | 7.9      | 36       | 9.8      |
| 4 Bowel Bleeding                      | <11      | <2.9     | <11      | <2.9     | 12       | 3.3      |
| 5 Hydronephrosis                      | 0        | 0.0      | 0        | 0.0      | 0        | 0.0      |
| 6 Urinary Fistula                     | 0        | 0.0      | 0        | 0.0      | 0        | 0.0      |
| 7 Bowel Fistula                       | 0        | 0.0      | 0        | 0.0      | 0        | 0.0      |

1 Lower Urinary Tract Obstruction included medical claim of dilation, urethrotomy, urethroplasty, sphincterotomy; transurethral prostate resection/ablation; urethral stent; or injection for stricture occurring. 328 men had no prior history of urinary obstruction prior to cryotherapy.

2 Erectile Dysfunction included medical claim for penile prosthesis or intracavernosal. 349 men had no prior history of erectile dysfunction prior to cryotherapy.

3 Urinary Incontinence included a medical claim of urethra sphincter injection, artificial sphincter, or incontinence repair (sling, urethroplasty) occurring. 368 men had no prior history of urinary incontinence prior to cryotherapy.

4 Bowel bleeding included hemorrhage or inflammation. 359 men did not have bowel bleeding prior to cryotherapy.

5 Hydronephrosis is distention of the renal pelvic and calices of the kidney with urine.

6 Bowel Fistula included medical claims of rectal repair, colostomy or ulcer.

7 Urinary Fistula was defined as medical claims with repair of bowel-bladder fistula or closure of urethroscopy or urethrocattaneous fistula occurring.
# Table 5

Medical codes regarding diagnoses and corrective invasive procedures for complications occurring after cryotherapy as initial treatment for prostate cancer

Definitions of complications following cryotherapy.

| Complications                                      | Medical Codes                                      |
|----------------------------------------------------|----------------------------------------------------|
| **Erectile**                                       |                                                    |
| Impotence, dysfunction                             | 607.84                                             |
| Penile Prosthesis                                  | 64.94, 64.95, 64.96, 64.97                         |
| Penile Prosthesis                                  | 54400, 54401, 54402, 54405, 54407, 54408, 54409, 54410, 54411, 54415, 54416, 54417, C1007, C1813, C2622, C3500, C8514, C8516, C8534, L7900 |
| Intracavernosal injection                          |                                                    |
|                                                    | 54231, 54235, J0270, J0275, J2440, J2760            |
| **Lower Urinary Tract Obstruction**                |                                                    |
| Stricture, obstruction, retention                  | 596.0, 598.x, 599.6, 788.2x                        |
| Dilation, urethrotomy, urethroplasty, sphincterotomy | 57.85, 57.91, 57.92, 58.0, 58.1, 58.3x, 58.44, 58.46, 58.47, 58.5, 58.6, 58.99, 60.95 |
| Transurethral prostate resection/destruction       | 60.2x                                              |
| Urethral Stent                                      | 52601, 52612, 52614, 52620, 52630, 53850, 53852    |
| Injection for Stricture                            | 2282                                               |
| **Urinary Incontinence**                           |                                                    |
| Incontinence, sphincter, deficiency                | 788.3x, 599.82                                      |
| Urethra, sphincter injection                       | 59.72                                              |
| Artificial sphincter                               | 53445, 53447                                       |
| Incontinence repair (sling, urethroplasty)         | 59.3, 59.4, 59.5, 59.6, 59.71, 59.79               |
| Urinary Fistula                                    | 596.1, 596.2, 599.1                                |
| Urethral fistula                                    | 59.73, 57.84, 58.43                                |
| Intestinovesical fistula                           | 5961                                               |
| Vesical fistula NEC                                | 5962                                               |
| Repair of a bowel-bladder fistula or closure of urethrostomy | 5783, 5784, 5843                              |
| **Bowel Fistula**                                  |                                                    |
| Fistula, ulcer                                     | 569.41, 569.81                                     |
| Rectal repair, colostomy                           | 48.73, 48.93                                       |
| **Hydronephrosis**                                 |                                                    |
| Distention of the renal pelvic and calices of the kidney with urine | 46.1x, 48.31, 48.32, 48.33 |
| **Bowel Bleeding**                                |                                                    |
| Hemorrhage, inflammation                           | 558.1, 569.3, 578.9                                |
ICD-9-CM = International Classification of Diseases, 9th revision, Clinical Modification
CPT = Current Procedural Terminology
HCPCS = Health Care Financing Administration Common Procedure Coding System

Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2012 June 01.